Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.

Moyle, Matthew; Cevikbas, Ferda; Harden, Jamie L; Guttman-Yassky, Emma

Moyle, Matthew; Cevikbas, Ferda; Harden, Jamie L; Guttman-Yassky, Emma.

Affiliation

Moyle M; Aravax, Melbourne, Victoria, Australia.
Cevikbas F; Dermira, Inc., Menlo Park, California.
Harden JL; Dermira, Inc., Menlo Park, California.
Guttman-Yassky E; Icahn School of Medicine at Mount Sinai, New York City, New York.

Exp Dermatol ; 28(7): 756-768, 2019 07.

Article in En | MEDLINE | ID: mdl-30825336

Subject(s)

Biological Products/therapeutic use; Dermatitis, Atopic/immunology; Dermatitis, Atopic/therapy; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal, Humanized/pharmacology; Antibodies, Monoclonal, Humanized/therapeutic use; Biomarkers/metabolism; Clinical Trials as Topic; Cytokines/metabolism; Humans; Immunity, Innate; Immunosuppressive Agents/therapeutic use; Interleukin-13/immunology; Interleukin-4/immunology; Lymphocytes/immunology; Lymphocytes/metabolism; Quality of Life; Skin/immunology; Treatment Outcome

Key words

atopic dermatitis; dupilumab; interleukin 13; interleukin 4; lebrikizumab; tralokinumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Products / Dermatitis, Atopic Type of study: Prognostic_studies Limits: Humans Language: En Journal: Exp Dermatol Journal subject: DERMATOLOGIA Year: 2019 Type: Article Affiliation country: Australia

Fulltext

XML

PubMed Links

Search on Google